Charting the Future of COVID-19: Is "Back to Normal" Within Reach?

Real VisionJanuary 25, 2021
How effective are the different COVID-19 vaccines? How does the science suggest we best move forward – and when will the world itself be rid of this deadly disease? In this interview, James Rasteh, founder and chief investment officer of Coast Capital, welcomes Justin Stebbing, professor of Cancer Medicine and Oncology at the Imperial College of London, to explore these critical questions. Stebbing gives a rigorous overview of the unique transmissibility and fatality rates of the virus and how the efficacies of the various vaccines, which are generally high, mean that a "back to normal" scenario is somewhat likely by around April 2021. Nevertheless, Stebbing thinks it is will be extremely difficult to eradicate COVID-19 completely and that, simply put, "coronavirus is here to stay." Filmed on January 20, 2021. Key learnings: The plurality of highly-efficacious vaccines means a return to normal is within sight. But yearly booster shots will likely be required, and full eradication will be extremely difficult—if not impossible.
Get access to daily trading ideas, trending topics, interviews and more!
Please subscribe to Canadian Insider Club Ultra

More Ultra Money Videos

Real VisionFebruary 26, 2021
Will Rising Interest Rates Change The Game?
Real Vision senior editor Ash Bennington hosts managing editor Ed Harrison and editor Jack Farley for a deep-dive on how rapidly rising interest rates are transforming the financial landscape before our very eyes. Ed and Ash analyze the latest economic data on rising personal income and share their views on the proposed $15 minimum wage that failed to make it into the stimulus bill. Jack and Ash review price action in stocks and commodities and explain how interest rates are like a financial gravity of sorts. Jack and Ed talk about how rising rates are creating tremendous change within the fixed income market. Lastly, the three discuss ARK Innovation ETF and the Grayscale Bitcoin Trust’s falling below net asset value.
Real VisionFebruary 26, 2021
Grantham's GMO: Twilight of Growth Stocks
In the wake of interviews with Jeremy Grantham and his recent heir apparent Ben Inker, managing editor Ed Harrison welcomes a third member of GMO, portfolio manager Matt Kadnar, to Real Vision. Kadnar shares with Harrison his approach to asset allocation and risk management at this unique market juncture. Kadnar thinks a cyclical bout of inflation could be due, but is skeptical that a 1970s-era level of secular inflation will linger for long since these serious periods of inflation are caused by a wage price spiral and unemployment remains high. Kadnar argues that if the market prices in more inflation, interest rates will continue to rise, and this will likely cause high-flying growth stocks to return to the ground. This is in line with Kadnar’s investment framework, which as he describes to Harrison is dependent on mean reversion in the long-run. Kadnar is not a believer in gold but notes that if real rates become sufficiently negative, gold begins to make more sense within a portfolio. Filmed on February 23, 2021. Key learnings: Kadnar believes that value stocks will likely outperform growth stocks over the long-run. He argues that Treasury bonds do not offer the same protection from equity drawdowns that they once did, and as such, he is constructive on asset backed-securities to play this role.
Real VisionFebruary 25, 2021
Stocks Follow Bonds Into the Slaughterhouse
Real Vision managing editor Ed Harrison welcomes James Bianco, president of Bianco Research, to the Daily Briefing to make sense of the massive rout in long-dated Treasury bonds that is perturbing every aspect of the market—from high-flying growth names like Tesla to gold to Treasury inflation-protected securities (TIPS). Bianco connects bond market indigestion to that lingering question around inflation, and hazards that industrials and financials will fare the best on a relative basis. Bianco and Harrison look at the Fed Fund futures, which indicate that the market is pricing in a rate hike. They also discuss the outflows out of the series of ARK innovation ETFs.

Get a Canadian Insider Club Ultra subscription for

  • Insider filing email alerts
  • Access to premium INK Research reports
  • Full access to weekly North America Top filer reports
  • Ad-free browsing
  • INK Ultra Money premium content

(already an Ultra member? Please log into your account for access)


Top